ECSP099828A - Uso de ranolazina para peptido natriuretico tipo-cerebral elevado - Google Patents

Uso de ranolazina para peptido natriuretico tipo-cerebral elevado

Info

Publication number
ECSP099828A
ECSP099828A EC2009009828A ECSP099828A ECSP099828A EC SP099828 A ECSP099828 A EC SP099828A EC 2009009828 A EC2009009828 A EC 2009009828A EC SP099828 A ECSP099828 A EC SP099828A EC SP099828 A ECSP099828 A EC SP099828A
Authority
EC
Ecuador
Prior art keywords
ranolazine
cerebral
natural peptide
elevated type
coronary
Prior art date
Application number
EC2009009828A
Other languages
English (en)
Inventor
Brent Blackburn
Marcus Jerling
Andrew Wolff
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Publication of ECSP099828A publication Critical patent/ECSP099828A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se encuentra orientada al uso de ranolazina para reducir el riesgo de accidentes adversos coronarios en un paciente mamífero. Típicamente, los péptidos natriuréticos se encuentran asociados con la enfermedad coronaria, sindrome coronario agudo, y/o disfunción diastólica. La ranolazina puede ser administrada a un paciente como una solución intravenosa o en una forma posológica oral.
EC2009009828A 2007-05-31 2009-12-28 Uso de ranolazina para peptido natriuretico tipo-cerebral elevado ECSP099828A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94121007P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
ECSP099828A true ECSP099828A (es) 2010-01-29

Family

ID=39929825

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009828A ECSP099828A (es) 2007-05-31 2009-12-28 Uso de ranolazina para peptido natriuretico tipo-cerebral elevado

Country Status (12)

Country Link
US (1) US20080299195A1 (es)
EP (1) EP2170333B1 (es)
KR (1) KR20100033490A (es)
CN (1) CN101896181A (es)
CA (1) CA2689633A1 (es)
EA (1) EA200971073A1 (es)
EC (1) ECSP099828A (es)
ES (1) ES2402675T3 (es)
HK (1) HK1143066A1 (es)
IL (1) IL202493A0 (es)
WO (1) WO2008150565A2 (es)
ZA (1) ZA200908657B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
EP0714660B1 (en) * 1989-06-23 2002-09-04 Syntex (U.S.A.) LLC Ranolazine and related piperazines for protecting skeletal muscles
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US20050245502A1 (en) * 1999-08-23 2005-11-03 Phoenix Biosciences Treatments for viral infections
US6803457B1 (en) * 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
US6528511B2 (en) * 2000-02-18 2003-03-04 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20030220312A1 (en) * 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
AU2001278045B2 (en) * 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
BR0206644A (pt) * 2001-01-26 2004-02-25 Schering Corp Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
DE10126328A1 (de) * 2001-05-30 2002-12-12 Infineon Technologies Ag Integrierte, abstimmbare Kapazität
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
WO2003066035A2 (en) * 2002-02-08 2003-08-14 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
RU2308976C2 (ru) * 2002-02-15 2007-10-27 Си Ви Терапьютикс, Инк. Полимерное покрытие для медицинских устройств
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2004079372A1 (en) * 2003-03-05 2004-09-16 Metabolex Inc. Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp
EP2377528B1 (en) * 2003-06-12 2014-02-19 The Board of Regents of the University of Colorado Fatty acid metabolism inhibitors for use in the treatment of cancer
WO2005002597A1 (en) * 2003-07-02 2005-01-13 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
ES2258365B1 (es) * 2003-10-03 2007-12-01 Lacer, S.A. Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos.
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
SG156681A1 (en) * 2004-11-09 2009-11-26 Cv Therapeutics Inc Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20100130436A1 (en) * 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
MX2011012140A (es) * 2009-05-14 2012-02-28 Gilead Sciences Inc Ranolazina para el tratamiento de problemas del snc.

Also Published As

Publication number Publication date
EP2170333A2 (en) 2010-04-07
WO2008150565A2 (en) 2008-12-11
ZA200908657B (en) 2010-08-25
EA200971073A1 (ru) 2010-08-30
CN101896181A (zh) 2010-11-24
US20080299195A1 (en) 2008-12-04
KR20100033490A (ko) 2010-03-30
ES2402675T8 (es) 2013-06-25
EP2170333B1 (en) 2013-02-20
AU2008260480A1 (en) 2008-12-11
ES2402675T3 (es) 2013-05-07
WO2008150565A3 (en) 2009-04-02
HK1143066A1 (en) 2010-12-24
CA2689633A1 (en) 2008-12-11
IL202493A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
ECSP099828A (es) Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
CO6541566A2 (es) Composición farmacéutica que comprende un agonista de glp -1 y metionina
CL2015000428A1 (es) Uso de un anticuerpo inhibidor de la dimerización de her2 para preparar medicamento para extender el tiempo de progresion de una enfermedad (ttp) o supervivencia en un paciente con cancer de mama metastasico (mbc) (div. sol. n°399-06).
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
AR053803A1 (es) Uso de acido pinolenico
AR077764A1 (es) Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos
CL2007001614A1 (es) Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
CL2012003641A1 (es) Compuesto analogo de glucagon que comprende sustituciones de los residuos aminoacidos en las posiciones 3 y/o 4 del glucagón nativo y que tiene actividad en el receptor de glucagon y/o el receptor de glp-1; composicion farmaceutica que comprende el compuesto; uso del compuesto para prevenir aumento de peso o promover perdida de peso en un sujeto que lo necesita.
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
AR081200A1 (es) Formulaciones de insulina de accion prolongada
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
CY1113755T1 (el) Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
CL2015002914A1 (es) Tratamiento de la diabetes mellitus mediante formulaciones de la insulinas de acción prolongada
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
AR061352A1 (es) El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv